AU2021232100A1 - Crystalline hydrate of a JAK inhibitor compound - Google Patents
Crystalline hydrate of a JAK inhibitor compound Download PDFInfo
- Publication number
- AU2021232100A1 AU2021232100A1 AU2021232100A AU2021232100A AU2021232100A1 AU 2021232100 A1 AU2021232100 A1 AU 2021232100A1 AU 2021232100 A AU2021232100 A AU 2021232100A AU 2021232100 A AU2021232100 A AU 2021232100A AU 2021232100 A1 AU2021232100 A1 AU 2021232100A1
- Authority
- AU
- Australia
- Prior art keywords
- crystalline hydrate
- lung
- compound
- disease
- transplant rejection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062983931P | 2020-03-02 | 2020-03-02 | |
| US62/983,931 | 2020-03-02 | ||
| PCT/US2021/070207 WO2021178991A1 (en) | 2020-03-02 | 2021-03-01 | Crystalline hydrate of a jak inhibitor compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021232100A1 true AU2021232100A1 (en) | 2022-10-20 |
Family
ID=75143791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021232100A Abandoned AU2021232100A1 (en) | 2020-03-02 | 2021-03-01 | Crystalline hydrate of a JAK inhibitor compound |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11702415B2 (https=) |
| EP (1) | EP4114836B1 (https=) |
| JP (1) | JP7681613B2 (https=) |
| KR (1) | KR20220149585A (https=) |
| CN (1) | CN115190878B (https=) |
| AR (1) | AR121483A1 (https=) |
| AU (1) | AU2021232100A1 (https=) |
| BR (1) | BR112022017398A2 (https=) |
| CA (1) | CA3172338A1 (https=) |
| CL (1) | CL2022002368A1 (https=) |
| CO (1) | CO2022012476A2 (https=) |
| IL (1) | IL295613A (https=) |
| MX (1) | MX2022010795A (https=) |
| PH (1) | PH12022552261A1 (https=) |
| TW (1) | TW202144343A (https=) |
| WO (1) | WO2021178991A1 (https=) |
| ZA (1) | ZA202209617B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3837258T3 (fi) * | 2018-09-04 | 2024-05-27 | Theravance Biopharma R&D Ip Llc | Dimetyyliaminoatsetidiiniamideja jak-estäjinä |
| TW202144343A (zh) * | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| US20230381280A1 (en) * | 2020-12-04 | 2023-11-30 | Centurion Ilaç Sanayi Ve Ticaret Anonim Sirketi | New dosage regimen for inhaled vasoactive intestinal polypeptide |
| WO2023230236A1 (en) | 2022-05-26 | 2023-11-30 | Theravance Biopharma R&D Ip, Llc | Process for preparing jak inhibitors and intermediates thereof |
| CN116785290B (zh) * | 2023-02-01 | 2024-02-13 | 银谷制药有限责任公司 | 苯环喹溴铵及其异构体在制备眼用制剂中的应用 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| CN119438457B (zh) * | 2024-12-18 | 2025-12-02 | 成都迈科康生物科技有限公司 | 一种测定脂质体佐剂中有关物质的方法及其应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| EP1648455A4 (en) | 2003-07-23 | 2009-03-04 | Exelixis Inc | MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| WO2010114971A1 (en) | 2009-04-03 | 2010-10-07 | Sepracor Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| LT3001903T (lt) | 2009-12-21 | 2018-01-10 | Samumed, Llc | 1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| SI3077395T1 (en) | 2013-12-05 | 2018-03-30 | Pfizer Inc. | Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides |
| KR20170002623A (ko) | 2014-05-14 | 2017-01-06 | 화이자 인코포레이티드 | 피라졸로피리딘 및 피라졸로피리미딘 |
| WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
| KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| WO2017077283A1 (en) | 2015-11-03 | 2017-05-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| DK3371185T3 (da) * | 2015-11-03 | 2020-11-30 | Topivert Pharma Ltd | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus-kinase-inhibitorer |
| UA123633C2 (uk) | 2015-11-03 | 2021-05-05 | Тереванс Байофарма Ар Енд Ді Айпі, Елелсі | Сполуки інгібітору jak-кінази для лікування респіраторного захворювання |
| US20180258546A1 (en) | 2017-03-09 | 2018-09-13 | Lam Research Corporation | Electroplating apparatus and methods utilizing independent control of impinging electrolyte |
| WO2018165392A1 (en) * | 2017-03-09 | 2018-09-13 | Theravance Biopharma R&D Ip, Llc | Jak inhibitors containing a 4-membered heterocyclic amide |
| WO2018204233A1 (en) | 2017-05-01 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a jak inhibitor compound |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| KR20200003121A (ko) | 2017-05-01 | 2020-01-08 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 저해제 화합물의 결정형 |
| FI3837258T3 (fi) | 2018-09-04 | 2024-05-27 | Theravance Biopharma R&D Ip Llc | Dimetyyliaminoatsetidiiniamideja jak-estäjinä |
| JP2021535176A (ja) | 2018-09-04 | 2021-12-16 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋ阻害剤およびその中間体を調製するためのプロセス |
| UA127328C2 (uk) | 2018-09-04 | 2023-07-19 | Тереванс Байофарма Ар Енд Ді Айпі, Елелсі | 5-7-членні гетероциклічні аміди як інгібітори jak |
| KR20210084512A (ko) | 2018-10-29 | 2021-07-07 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제로서 2-아자비시클로 헥산 화합물 |
| HUE067145T2 (hu) | 2019-02-25 | 2024-10-28 | Henan Medinno Pharmaceutical Tech Co Ltd | JAK inhibitor vegyület és alkalmazása |
| WO2020181034A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
| CN112279848A (zh) | 2019-07-25 | 2021-01-29 | 四川海思科制药有限公司 | 一种泛JAKs抑制剂及其用途 |
| TW202144343A (zh) * | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| CN115803023A (zh) | 2020-05-08 | 2023-03-14 | 施万生物制药研发Ip有限责任公司 | 发用奈珠西替尼治疗感染冠状病毒的患者的方法 |
| WO2022271604A1 (en) | 2021-06-21 | 2022-12-29 | Theravance Biopharma R&D Ip, Llc | Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l |
-
2021
- 2021-02-26 TW TW110106884A patent/TW202144343A/zh unknown
- 2021-03-01 CN CN202180017759.9A patent/CN115190878B/zh active Active
- 2021-03-01 AU AU2021232100A patent/AU2021232100A1/en not_active Abandoned
- 2021-03-01 US US17/249,375 patent/US11702415B2/en active Active
- 2021-03-01 KR KR1020227034088A patent/KR20220149585A/ko active Pending
- 2021-03-01 AR ARP210100530A patent/AR121483A1/es unknown
- 2021-03-01 EP EP21713868.4A patent/EP4114836B1/en active Active
- 2021-03-01 JP JP2022552324A patent/JP7681613B2/ja active Active
- 2021-03-01 MX MX2022010795A patent/MX2022010795A/es unknown
- 2021-03-01 WO PCT/US2021/070207 patent/WO2021178991A1/en not_active Ceased
- 2021-03-01 CA CA3172338A patent/CA3172338A1/en active Pending
- 2021-03-01 PH PH1/2022/552261A patent/PH12022552261A1/en unknown
- 2021-03-01 BR BR112022017398A patent/BR112022017398A2/pt unknown
- 2021-03-01 IL IL295613A patent/IL295613A/en unknown
-
2022
- 2022-08-29 ZA ZA2022/09617A patent/ZA202209617B/en unknown
- 2022-08-31 CL CL2022002368A patent/CL2022002368A1/es unknown
- 2022-08-31 CO CONC2022/0012476A patent/CO2022012476A2/es unknown
-
2023
- 2023-05-31 US US18/326,732 patent/US12122773B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN115190878B (zh) | 2024-10-29 |
| AR121483A1 (es) | 2022-06-08 |
| CA3172338A1 (en) | 2021-09-10 |
| US11702415B2 (en) | 2023-07-18 |
| JP7681613B2 (ja) | 2025-05-22 |
| JP2023516640A (ja) | 2023-04-20 |
| ZA202209617B (en) | 2023-04-26 |
| US20240025897A1 (en) | 2024-01-25 |
| WO2021178991A1 (en) | 2021-09-10 |
| KR20220149585A (ko) | 2022-11-08 |
| CN115190878A (zh) | 2022-10-14 |
| CL2022002368A1 (es) | 2023-04-21 |
| PH12022552261A1 (en) | 2023-11-13 |
| US20210269437A1 (en) | 2021-09-02 |
| IL295613A (en) | 2022-10-01 |
| BR112022017398A2 (pt) | 2022-10-18 |
| EP4114836C0 (en) | 2025-01-08 |
| US12122773B2 (en) | 2024-10-22 |
| EP4114836A1 (en) | 2023-01-11 |
| EP4114836B1 (en) | 2025-01-08 |
| MX2022010795A (es) | 2022-11-30 |
| CO2022012476A2 (es) | 2022-09-20 |
| TW202144343A (zh) | 2021-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12122773B2 (en) | Crystalline hydrate of a JAK inhibitor compound | |
| US12398135B2 (en) | Dimethyl amino azetidine amides as JAK inhibitors | |
| US11713315B2 (en) | 5 to 7 membered heterocyclic amides as JAK inhibitors | |
| CA3053853C (en) | Dimethyl amino azetidine amides and 5 to 7 membered heterocyclic amides as jak inhibitors | |
| EA040902B1 (ru) | 5-7-членные гетероциклические амиды в качестве ингибиторов jak | |
| EA040464B1 (ru) | Амиды диметиламиноазетидина в качестве jak ингибиторов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |